Key Insights

• The considerable ownership by individual investors in G1 Therapeutics indicates that they collectively have a greater say in management and business strategy

• 35% of the business is held by the top 25 shareholders

• Recent sales by insiders

To get a sense of who is truly in control of G1 Therapeutics, Inc. (NASDAQ:GTHX), it is important to understand the ownership structure of the business. With 60% stake, individual investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Following a 47% decrease in the stock price last week, individual investors suffered the most losses, but institutions who own 25% stock also took a hit.

Let's take a closer look to see what the different types of shareholders can tell us about G1 Therapeutics.

See our latest analysis for G1 Therapeutics

What Does The Institutional Ownership Tell Us About G1 Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in G1 Therapeutics. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at G1 Therapeutics' earnings history below. Of course, the future is what really matters.

Hedge funds don't have many shares in G1 Therapeutics. Our data shows that Eshelman Ventures, LLC is the largest shareholder with 8.7% of shares outstanding. With 5.7% and 3.8% of the shares outstanding respectively, MedImmune Ventures, Inc. and The Vanguard Group, Inc. are the second and third largest shareholders.

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of G1 Therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.